Table 2.
Prevalence of Drug Resistance Mutations among 470 ART‐naive participants
| Type | # With mutations | Prevalence (95% CI) (n = 470) | |
|---|---|---|---|
| Total with any HIVDR | 77 | 16.4% (13.2 to 20.0) | |
| Total with SDRM | 46 | 9.8% (7.3 to 12.9) | |
| NNRTI SDRMs | 9.3% (6.9 to 12.4) | ||
| K103N/S | 34 | 7.4% (5.2 to 10.2) | |
| G190A/E | 6 | 1.3% (0.5 to 2.8) | |
| K101E | 3 | 0.6% (0.1 to 1.9) | |
| Y181C | 1 | 0.2% (0.0 to 1.2) | |
| Y188C | 1 | 0.2% (0.0 to 1.2) | |
| NRTI SDRMs | 1.3% (0.5 to 2.8) | ||
| M184V | 4 | 0.9% (0.2 to 2.2) | |
| T215F/Y | 2 | 0.4% (0.1 to 1.5) | |
| D67N | 1 | 0.2% (0.0 to 1.2) | |
| K70R | 1 | 0.2% (0.0 to 1.2) | |
| L74I | 1 | 0.2% (0.0 to 1.2) | |
| V75M | 1 | 0.2% (0.0 to 1.2) | |
| K219Q | 1 | 0.2% (0.0 to 1.2) | |
| Any TAM | 5 | 1.1% (0.3 to 2.5) | |
HIVDR, HIV Drug Resistance; SDRM, Surveillance Drug Resistance Mutations; TAMs, Thymidine analogue mutations, including both Type I and Type II.